The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles

Kiran Musunuru, Roger S. Blumenthal

Research output: Contribution to journalReview article

Abstract

To outward appearances, the publication of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial has led to a monolithic backlash against the use of ezetimibe by cardiologists for the treatment of hyperlipidemia. Rather than be swayed by popular opinion, we should each put the results of ENHANCE into context and ask the questions: should I put my trust in an imaging surrogate or in low-density lipoprotein (LDL) cholesterol (LDL-C), and how do the safety and efficacy of ezetimibe compare with other nonstatin lipid-lowering agents?

Original languageEnglish (US)
Pages (from-to)288-290
Number of pages3
JournalClinical Cardiology
Volume31
Issue number6
DOIs
StatePublished - Jun 1 2008

Keywords

  • ENHANCE trial
  • Ezetimibe
  • Hypercholesterolemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The implications of the ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression trial: A return to first principles'. Together they form a unique fingerprint.

  • Cite this